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Introduction
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TC-
DD) has been identified as a toxic contamin-
ant of chlorophenols and related hydro-
carbons that are widely used in agriculture
and industry. It has been implicated in
various diseases, including human cases of
chloracne (1) and porphyria cutanea tarda
(2) and in chick edema (3). Its teratogenic-
ity has been documented in rats (4) and
mice (5). Monkeys fed toxic fat, later found
to contain TCDD and other chlorinated de-
rivatives of dibenzo-p-dioxin, were observed
to undergo a decrease in the cellular elements
of the bone marrow and the peripheral blood
(6). in contrast, increases in hematocrit
and leukocyte count were observed in rats
treated with TCDD (7). Depression of blood
platelets in TCDD-treated rats and guinea
pigs has been recently observed (8). The
present studies were undertaken in order to
characterize hematologic changes and in
particular platelet function alterations in
rats exposed to TCDD.
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Methods
Animals
Female CD rats, weighing 150-175 g, re-
ceived daily oral doses of TCDD in an ace-
tone-corn oil mixture at a level of 10 /Lg/kg.
Control rats received an equivalent dose of
acetone and corn oil. On days 10 and 14 of
treatment animals were anesthetized with
methoxyflurane, and blood was withdrawn
by cardiac puncture.
Marrow Megakaryocyte Studies
Bone marrow preparations were made as
described by Eurenius (9), and smears were
prepared with a Wright-Leishman-Giemsa
stain.
Platelet Function Studies
Bleeding times were determined on anes-
thetized animals. Lacerations were made on
the ear with a blood lancet, and puncture
sites were blotted with filter paper at 30-sec
intervals until bleeding stopped. Clot re-
traction was determined as described in the
literature (10). Platelet factor III activity
was evaluated with the prothrombin con-
sumption test (11) performed on blood that
was allowed to clot with and without
added Inosithin. Platelet aggregation was
determined macroscopically in a mixture
containing, in a final volume of 0.5 ml, 0.1
/umole ADP, 1.0 fanole calcium chloride,
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platelet-rich plasma with a final platelet
concentration of 200,000/mm3.
Prothrombin times were performed as
described in the literature (12). Factor X
assays were performed by measuring clotting
time in a mixture containing test serum,
0.1 ml, factor X-deficient plasma (Dade),
0.1 ml, and Simplastin (General Diagnos-
tics), 0.2 ml.
Fibrinogen Degradation Products
Fibrinogen degradation products were
assayed in the serum of control and treated
rats by using the Wellcome FDP Kit (Bur-
roughs-Wellcome), which employs a hem-
agglutination-inhibition system.
Other hematologic parameters were de-
termined by routine methods.
Statistical analysis was performed by the
Student's t test.
Results
Red cell parameters of control and
treated rats are given in Table 1. Packed
cell volumes were elevated in TCDD-treated
rats at days 10 and 14 of treatment. Similar-
ly, erythrocyte counts were increased in the
treatment as compared to control groups at
days 10 and 14. Reticulocyte counts differed
significantly at day 14, presumably repre-
senting lowered values in the control animals.
Mean corpuscular volume and mean cor-
puscular hemoglobin were significantly de-
pressed in treatment groups at day 10 but
not day 14. TCDD-treated rats did not differ
significantly from controls with regard to
either hemoglobin or mean corpuscular
hemoglobin concentration.
White cell parameters of control and
treated rats are given in Table 2. Total
leukocyte counts were elevated, but not
significantly, in TCDD-treated animals at
10 and 14 days. Neutrophil counts were
significantly increased in both treatment
groups when compared to controls. Lympho-
cyte and monocyte counts were elevated in
rats treated 10 and 14 days, and eosinophil
counts were slightly depressed. These differ-
ences, however, were not statistically signi-
ficant.
Table 3 demonstrates that platelet counts
were significantly lowered in treated rats
at days 10 and 14. Bone marrow prepara-
tions did not show a corresponding decrease
in megakaryocyte numbers of animals
treated 14 days. Megakaryocyte size and
numbers of nuclei per megakaryocyte were
also evaluated, and these were observed to
be equivalent in control and treatment
groups.
Bleeding times were equivalent in treated
and control rats at day 14. These results
are presented in Table 4. Clot retraction
was diminished in both 10-day and 14-day
treatment groups compared to controls. The
velocity of platelet aggregation was not
significantly altered in TCDD-treated rats.
Table 1. Red cell parameters in rats administered daily oral doses of TCDD of 10/Ag/kg.a
10 Days 14 Days
Control Treated Control Treated
Hemoglobin, g/100 ml 12.3 ± 0.7 13.5 ± 0.8 12.6 ± 1.2 14.8 ± 1.4
Packed cell volume, % 37.4 ± 2.3 43.4 ± 3.7* 36.6 ± 2.3 45.0 ± 4.0*
Erythrocyte count X 10-8, 5.0 ± 0.5 6.7 ± 0.4** 5.2 ± 0.3 6.2 ± 0.7*
per mm'
Reticulocyte count, % 4.2 ± 1.2 4.1 ± 1.0 1.5 ± 0.6 3.3 ± 1.2*
Mean corpuscular volume, A' 75.8 ± 4.1 65.0 ± 7.0* 71.1 ± 1.8 73.0 ± 2.2
Mean corpuscular Hb con- 32.8 ± 1.4 31.2 ± 1.7 34.5 ± 1.3 32.9 ± 1.4
centration, %.
Mean corpuscular Hb, pg/cell 24.9 ± 1.2 20.2 ± 1.1** 24.5 ± 0.9 24.3 ± 1.6
aValues presented are means ± standard deviation. Four animals were tested in each group. Values
marked with asterisks differ significantly from control values: *P <0.05; **P <0.01.
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of 10 ,g/kg.'
10 Days 14 Days
Control Treated Control Treated
Leukocyte count X 10' per 4.6 ± 1.5 9.4 ± 4.2 5.1 ± 2.6 9.2 ± 2.1
mm'
eTeutrophil count X 10-' per 0.5 ± 0.1 0.9 ± 0.3* 0.6 ± 0.3 2.7 ± 1.5*
mm'
Lymphocyte count X 10-' per 3.9 ± 1.4 8.1 ± 3.9 4.3 ± 2.4 6.1 ± 1.3
mm'
Nlonocyte count per mm' 137 ± 92 254 ± 182 89 ± 50 243 ± 135
Eosinophil count per mm' 61 ± 31 21 ± 36 77 ± 39 65 ± 55
a Values presented are means ± standard deviation. Four animals were tested in each group. Values
marked with an asterisk differ significantly from control values at a level of P <0.05.
Table 3. Effect of daily oral doses of TCDD of 10 ,.g/kg upon marrow megakaryocytes
and blood platelets in rats.a
10 Days 14 Days
Control Treated Control Treated
Platelet count X 10-' 911 ± 100 427 ± 225* 688 ± 58 388 ± 124*
per mm'
Ategakaryocytes per 10- 444 ± 75 615 ± 219
nucleated marrow cells
aValues presented are means ± standard deviation. Four animals were tested in each group. Values
marked with an asterisk differ significantly from control values at a level of P <0.01.
However, prothrombin consumption tests re-
vealed markedly prolonged times, both with
ind without Inosithin, in rats from both
breatment groups. This contrasted with
3quivalent prothrombin times observed in
-ontrol and treated animals. No difference
in factor X levels between control and
treated rats was observed at 14 days.
Serum fibrinogen degradation products
were not observed in either control or treat-
ment groups at days 10 and 14. Four animals
weretested in each group.
Discussion
The elevations in packed cell volumes and
erythrocyte counts of TCDD-treated rats
reported in the present study are consistent
with dehydration and consequent hemocon-
centration. These results are in agreement
with earlier investigations of TCDD (7).
Presumably, the previously reported depres-
sion of hematopoiesis in monkeys fed toxic
fat (6) represents species variation or the
effect of a different toxic contaminant.
The alterations in red cell indices and the
leukocytosis with neutrophilia, lymphocy-
tosis and eosinopenia that have been ob-
served in this study are nonspecific hemato-
logic changes consistent with widespread
toxicity of TCDD. Of interest is the ob-
served selective depression of blood platelets
in treated rats. In view of the finding of
normal marrow megakaryocytes, decreased
production of platelets in treated rats is
unlikely. It is possible that TCDD results
in disseminated intravascular coagulation
with thrombocytopenia due to the aggrega-
tion and incorporation of platelets into
platelet-fibrin microthrombi. However, the
absence of serum fibrinogen degradation
products in treated animals argues against
this possibility. Increased peripheral des-
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oral doses of TCDD of 10 ug/kg."
10 Days 14 Days
Control Treated Control Treated
Bleeding time, min 3.6 ± 0.9 4.1 ± 2.7
Clot retraction, % 73.6 ± 5.8 60.8 ± 4.3** 81.2 ± 6.0 69.8 + 4.3*
(7) (6)
Velocity of platelet aggre- 18.0 ± 1.4 26.0 ± 8.5 23.0 ± 6.4 51.2 ± 40.0
gation, sec (2) (2) (3)
Prothrombin time, sec 11.8 ± 0.5 11.7 + 1.9 11.7 + 1.8 13.5 ± 3.1
Prothrombin consumption 22.8 ± 6.7 58.5 ± 1.7*** 18.9 ± 3.6 53.0 ± 8.2***
test, sec
Prothrombin consumption 26.2 ± 9.3. 60.0 0.0*** 19.8 ± 6.8 51.9 ± 16.2*
test with Inosithin, sec
Factor X, sec - 19.0 ± 2.0 21.0 ± 0.0
(2) (2)
a Values presented are means ± standard deviation. Numbers in parentheses indicate number of animals
tested; in all other groups four animals were tested.
Values marked with asterisks differ significantly from control values: *P <0.02; **P <0.01;
***P <0.001.
truction of platelets due to an antibody
response is a possible mechanism for the
observed thrombocytopenia. Such a mechan-
ism is proposed in human cases of hyper-
sensitivity to quinidine and Sedormid (13).
The diminished clot retraction in TCDD-
treated animals is consistent with the ob-
served thrombocytopenia. Otherwise, plate-
let function, as assessed by bleeding time
and velocity of aggregation, was not altered.
Similarly, decreased platelet factor III
activity, which would be reflected in a
shortening of the prothrombin consumption
time that was corrected by the addition of
inosithin, was not observed in treated rats.
On the contrary, prothrombin consumption
times were consistently prolonged in the
treatment groups. In view of the normal
prothrombin times, this prolongation of pro-
thrombin consumption times is not readily
explainable. Factor X levels were normal in
treated animals. Deficiency or inactivation
of factor VII, which has been reported in
human cases of liver and renal failure and
after exposure to propylthiouracil, salicy-
lates and indanedione drugs (14), is a pos-
sibility. Prolongation of the prothrombin
consumption time in factor VII-deficient
dogs has been reported (15), but this
is accompanied by prolonged prothrombin
times. Similarly, deficiency or inactivation
of prothrombin might prolong the pro-
thrombin consumption test, but again, an
abnormal prothrombin time would be ex-
pected. It remains to perform factor VII
assays ahid other coagulation studies in
animals exposed to TCDD.
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